Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluticasone is a synthetic glucocorticoid corticosteroid available as two main esters—fluticasone propionate and fluticasone furoate. It is used in various formulations (inhalers, nasal sprays, topical creams) for the treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic and non-allergic rhinitis, and corticosteroid-responsive dermatoses[4][5][7][8]. The drug acts primarily by binding to glucocorticoid receptors to produce potent anti-inflammatory effects. This action leads to the downregulation of multiple inflammatory mediators such as histamine, cytokines, leukotrienes, chemokines, prostaglandins, and tryptase[6]. Fluticasone interrupts both early- and late-phase allergic responses by controlling gene expression related to inflammation[6]. It was first approved in 1990 (propionate) and 2007 (furoate)[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluticasone.